Regulation Of Haemopoietic And Immune Cells In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$19,924,984.00
Summary
This Program brings together a team of researchers with world-class multidisciplinary skills in biomedical discovery and an established track record of clinical and commercial translation of research discoveries. This Program will result in the creation of new knowledge regarding the control of blood and immune cell production and function and provide new avenues for the treatment of people suffering from cancers of the blood, inflammatory and immune disorders.
Bioreactors for manufacture of human platelets. Blood cell transfusion is a critical part of medicine that is supported by volunteer donors. Unfortunately, the demand for blood cells for transfusion far outstrips supply and therefore new strategies are required for manufacture of blood cells. This project will lead to the development of technology for manufacture of human platelets from stem cells. The systems devised will be applicable to a broad range of other blood cell types.
The Role Of Duffy And PF4 In The Platelet Killing Of Malaria Parasites.
Funder
National Health and Medical Research Council
Funding Amount
$350,045.00
Summary
Platelets in the blood can kill the Plasmodium parasite, which lives inside red blood cells and causes malaria. Platelets bind parasite-infected red cells and release a molecule that is toxic to the parasite. This project will study why a red cell molecule called Duffy is also needed for this function of platelets. Most Africans carry a gene for Duffy that stops its expression in red cells, and may therefore be more susceptible to malaria because their platelets cannot kill the malaria parasite.
Identifying Novel Antimalarial Targets Using ENU Mutagenesis In The Mouse
Funder
National Health and Medical Research Council
Funding Amount
$760,170.00
Summary
Malaria is estimated to cause 1.2 million deaths per year. The malarial parasite has developed resistance to most drugs and new drugs are needed. We aim to mimic the protective red blood cell diseases common in human populations in malarial endemic areas by identifying host targets that are important in parasite growth.
Mimetics and small chemical compounds for hemopoietic stem cell mobilisation. This project will result in the design and synthesis of new chemical compounds that could be used clinically to help collect blood stem cells for bone marrow transplantation. For patients this will mean more effective and less painful ways to collect stem cells and better transplant outcomes. There is a large, ongoing international market for this type of drug and likelihood of significant financial benefit.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100043
Funder
Australian Research Council
Funding Amount
$330,000.00
Summary
Development of an ultra-high speed spinning disk confocal micro-particle image velocimetry (PIV) platform for the investigation of cardiovascular disease . This facility will establish a microscope system specifically designed to investigate the function of blood cells in the context of cardiovascular diseases such as heart attack and stroke.
CARDIAC-ARIA : Measuring the accessibility to cardiovascular services in rural and remote Australia via applied geographical spatial technology (GIS). Despite significant improvements in the cardiovascular health of Australians, Cardiovascular Disease (CVD) continues to impose a heavy burden on Australians in terms of cost,disability and death. Recent evidence suggests that mortality from CVD increases with increasing remoteness. Rates are reported to be between 20% and 50% higher in rural areas ....CARDIAC-ARIA : Measuring the accessibility to cardiovascular services in rural and remote Australia via applied geographical spatial technology (GIS). Despite significant improvements in the cardiovascular health of Australians, Cardiovascular Disease (CVD) continues to impose a heavy burden on Australians in terms of cost,disability and death. Recent evidence suggests that mortality from CVD increases with increasing remoteness. Rates are reported to be between 20% and 50% higher in rural areas compared to major cities. This project, with its extensive use of Geographic Information Systems (GIS) technology, will rank 11,338 rural and remote population centres to identify geographical 'hotspots' where there is likely to be a mismatch between the demand for and actual provision of cardiovascular services.Read moreRead less